Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alpelisib + nab-paclitaxel
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Intravenous
01
Overview
Alpelisib + nab-paclitaxel is a combination therapy under investigation for the treatment of HER2-negative metastatic breast cancer, including triple-negative subtypes. Alpelisib is an oral, selective inhibitor of the phosphatidylinositol 3-kinase catalytic subunit alpha (PI3Kα), targeting tumors with PIK3CA mutations or PTEN loss. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor that disrupts cell division. The combination aims to overcome resistance mechanisms in breast cancer by simultaneously inhibiting PI3K signaling and disrupting mitosis. Clinical studies have shown this regimen to be well-tolerated with encouraging efficacy, particularly in patients harboring PIK3CA mutations[1][2][5]. The combination is being evaluated in phase II and III clinical trials for advanced/metastatic HER2-negative breast cancer[4][5].
- Other names
- alpelisib and nab-paclitaxelBYL719 and ABI-007BYL-719 and ABI-007BYL 719 and ABI-007
02
Targets
TUBB (Tubulin (alpha and beta subunits))PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on alpelisib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alpelisib + nab-paclitaxel.